Page 342 - Hematology_ Basic Principles and Practice ( PDFDrive )

284 Part III Immunologic Basis of Hematology

Dalakas MC: Mechanisms of action of IVIG and therapeutic considerations Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody
in the treatment of acute and chronic demyelinating neuropathies. of predefined specificity. Nature 256:495–497, 1975.
Neurology 59:S13, 2002. Kopf M, Abel B, Gallimore A, et al: Complement component C3 promotes
Fischer MB, Goerg S, Shen L, et al: Dependence of germinal center B cells T-cell priming and lung migration to control acute influenza virus infec-
on expression of CD21/CD35 for survival. Science 280:582, 1998. tion. Nat Med 8:373, 2002.
Gros P, Milder FJ, Janssen BJ: Complement driven by conformational Legendre CM, Licht C, Muus P, et al: Terminal complement inhibitor
changes. Nat Rev Immunol 8:48, 2008. eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med
Helmy KY, Gorgani NN, Kljavin NM, et al: CRIg: A macrophage comple- 368:2169–2181, 2013.
ment receptor required for phagocytosis of circulating pathogens. Cell Minard S, Papa SM, Campiglio M, et al: Biologic and therapeutic role of
124:915, 2006. HER2 in cancer. Oncogene 29:6570, 2003.
Hillmen P, Hall C, Marsh J, et al: Effect of eculizumab on hemolysis and Nixon A, Sexton D, Lander R: Drugs derived from phage display:
transfusion requirements in patients with paroxysmal nocturnal hemoglo- from candidate identification to clinical practice. MAbs 6:73–85,
binuria. N Engl J Med 350:552–559, 2004. 2014.
Hillmen P, Muus P, Duhrsen U, et al: Effect of the complement inhibitor Thiel S, Vorup-Jensen T, Stover CM: A second serine protease associated
eculizumab on thromboembolism in patients with paroxysmal nocturnal with mannan-binding lectin that activates complement. Nature 386:506,
hemoglobinuria. Blood 110(12):4123–4128, 2007. 1997.
Hopken UE, Lu B, Gerard NP, et al: The C5a chemoattractant receptor van den Elsen JM, Isenman DE: A crystal structure of the complex between
mediates mucosal defence to infection. Nature 383:86, 1996. human complement receptor 2 and its ligand C3d. Science 332:608,
Jordan SC, Vo AA, Peng A, et al: Intravenous gammaglobulin (IVIG): A 2011.
novel approach to improve transplant rates and outcomes in highly HLA-
sensitized patients. Am J Transplant 6:459, 2006.
Kang YS, Do Y, Lee HK, et al: A dominant complement fixation pathway REFERENCES
for pneumococcal polysaccharides initiated by SIGN-R1 interacting with
C1q. Cell 125:47, 2006. For the complete list of references, log on to www.expertconsult.com.
Kelsoe G: Life and death in germinal centers (redux). Immunity 4:107,
1996.
Kemper C, Chan AC, Green JM, et al: Activation of human CD4+ cells
with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature
421:388, 2003.